Navigation Links
Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42
Date:8/12/2008

$0.34 fully diluted earnings per share, reported in the third quarter of the prior year. Cash flow from operations for the quarter was $41.3 million, a 7 percent increase from the same period in 2007.

"Decisions by the Hillenbrand board to pay our first dividend as a new public company and authorize a $100 million share repurchase program demonstrate our commitment to using the company's strong cash flow to create and increase shareholder value," said Camp.

Outlook for Fiscal Year 2008

The company is reaffirming its revenue guidance for fiscal year 2008 of $668 to $686 million and increasing its guidance for GAAP net income from a range of $80 to $93 million to a range of $86 to $98 million as a result of lower-than-anticipated antitrust litigation and separation costs. On an adjusted basis, our guidance remains unchanged at earnings per share of $1.64 to $1.79.

Hillenbrand, Inc.

(Amounts in millions, except per share data)

Fiscal year ending September 30

FY 08 Range

FY 07 Low High

Net revenues $667 $668 $686

Income before taxes $157 $140 $159

Tax rate 36.6% 38.6% 38.1%

Net income $100 $86 $98

Diluted shares outstanding 63 63 63

Diluted net income per share $1.59 $1.36 $1.56

Excluding certain non-operating costs

(anti-trust litigation and separation*)

Net income $103 $113

Diluted net income per share $1.64 $1.79

*Non-GAAP Financial Disclosures and Reconciliations for Third Quarter Whil
'/>"/>

SOURCE Hillenbrand, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company
2. Hillenbrand, Inc. Names Joe A. Raver President and Chief Operating Officer of Batesville Casket Company
3. Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... grew out of a collaboration between UCLA engineer...he nearly 10 million Americans who suffer from per...rdening of the arteries, peripheral arterial disea...ch narrowed arteries reduce blood flow to the limb...ular disease, heart attack and stroke, and its pro...
(Date:11/25/2009)...too short to draw definite conclusions, experts sa...ws) -- In diabetic patients with blocked coronary ...comes at one year whether patients undergo bypass ...archers report. , Bypass surgery has been the s...ary artery disease. However, less invasive approac...
(Date:11/25/2009)...ation and treatment clinics to resume Monday, Nov....ovember 25, 2009 -- Centegra Health System is cont...ne shots at four Centegra Primary Care (CPC) vacci...as arrived. The clinics are at CPC sites in Huntle... open as follows: ,   From 4:30 to 7:3...
(Date:11/25/2009)...ological symptoms, study finds , , WEDN...de effects are among the potential problems faced ...re treated with cisplatin-based chemotherapy, a ne...orwegian men treated for unilateral testicular can...w-up survey conducted from 1998 to 2002. , The ...
(Date:11/25/2009)...re/-- MISSIONSkincare ®isproudtosupportGNC,se...NC,sannualSt.Jude ThanksandGiving campaign,$1fromt...ER-C(TM)LipBalm willbedonatedtoSt.Jude.Additionall...onationatcheckoutatoneoftheir5,000+retaillocations...Judeduringtheir2009 ThanksandGiving campaign. ,...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
...y, contrast-enhanced sonography compared with sono...sessment of blunt abdominal trauma.// Massimo... objective of our study was to prospectively compa...ts”. The study was conducted by the departme...
...d about subject as sex is, perhaps vying with each...act of stress is well known - responsible //for ma...ecently stress during pregnancy was thought to lea...en seem to be twice inclined to suffer PSTD and de...
...ced that the deadly H5N1 strain of bird flu has be...ria, which is the first African// country to be hi...been reported, experts fear that several cases hav...es in Taraba, one commercial farm and two places w...
...c study says ‘significant fluctuations in the firs...ncreases// the chances of death’. According to...ying diastolic blood pressure, which again is root...24 hours. Blood pressures were checked every five ...
...nt of Energy's Pacific Northwest National Laborato...s that the damage in neurodegenerative diseases// ...led nitration. It was explained that Parkinson's, ...idative stress, the cell damage that is usually ca...
...els will sashay down the catwalk alongside eight b...s Assam city// . Preparations are on for the ...e ornate Pragjyoti cultural centre in Guwahati. Yo...ippanita Sharma for company that day. "The e...
Other Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Fluctuating BP and Stroke Lowered Patient Survival Rate 2Health News:Scientist Optimistic In Breakthrough For Causes Of Neurodegenerative Diseases 2Health News:Blind Girl Students to Catwalk in Guwahati Fashion Show 2
(Date:11/25/2009)...--RegadoBiosciences,aprivatelyheldcompanyleadingth...rolagents,announcedthatDavidMazzo,PhD,CEOandPresid...lthCareConferenceattheNewYorkPalaceHotelinNewYorkC...onTuesday,December1andwillincludeanoverviewoftheCo...gram,theanticoagulantsystem,REG1.Thehealthcareindu...
(Date:11/25/2009).../--SwissrayInternational,Inc.aleadingmanufacturero...odaythatitsoperationshavebeenacquiredbyaprivateSwi...smedicalimagingbrand.Theacquisitionincludedallasse...ntory.After25yearsofsuccessandgrowthSwissrayisnowp...tswithstableandsteadygrowth. ,, "Swissrayhaslon...
(Date:11/25/2009)...nker.comannouncesthatanewmarketresearchreportisava...y-USMarketTrends&Analysis http://www.reportli...rket-Trends--Analysis.html ,, TheUSintranasald...ticapplicationsfromthedeliveryofconventionallocalt...rugs.Thefutureofthetechnologyhingesontotheeffectiv...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Gamida Cell and Cellerix Partner on Feasibility Study 14558 1Gamida Cell and Cellerix Partner on Feasibility Study 14558 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 3NASCSA Receives 24200 000 Grant From Purdue Pharma L P to Support State Prescription Drug Monitoring Programs 5633 1NASCSA Receives 24200 000 Grant From Purdue Pharma L P to Support State Prescription Drug Monitoring Programs 5633 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4
...ed Parenteral Product Ganite(R), BERKELEY HEIGHTS...A ) today announced that the Company has received ...pharmaceutical gallium compositions,and complexes ... U.S.,Patent 7,354,952 extends the intellectual pr... gallium-containing products that are intended,as ...
...R Annual Meeting, SOMERSET, N.J., April 14 Alfac...hat Dr. Intae Lee with the University of,Pennsylva...ase) could be a,promising radiation sensitizer for...clinical in vivo and in vitro data in a poster at ...AACR) Annual Meeting being held April 12 -,16 in S...
Other Medicine Technology:Genta Receives Key Patent Related to Oral Gallium Compound G4544 2Genta Receives Key Patent Related to Oral Gallium Compound G4544 3Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 2Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 3
Pediatric Ureteral Catheters
Silicone Universal Drainage Stents
Double Pigtail Stent Sets - Polyurethane
Koyle Diaper Stents
Medicine Products: